Stockscreener 앱 받기
15.14
0.26%
0.04
전일 마감가:
$15.10
열려 있는:
$15.3
하루 거래량:
197.13K
Relative Volume:
0.36
시가총액:
$193.61M
수익:
-
순이익/손실:
$-121.02M
주가수익비율:
-1.3446
EPS:
-11.26
순현금흐름:
$-114.09M
1주 성능:
-7.34%
1개월 성능:
-3.13%
6개월 성능:
-75.41%
1년 성능:
+32.46%
1일 변동 폭
$15.00
$15.59
1주일 범위
$14.98
$16.69
52주 변동 폭
$7.31
$69.97
토닉스 파마슈티컬스 홀딩 Stock (TNXP) Company Profile
명칭
Tonix Pharmaceuticals Holding Corp
전화
212-980-9155
주소
26 MAIN STREET, SUITE 101, CHATHAM, NY
Compare TNXP vs VRTX, REGN, ARGX, ALNY, ONC
| 주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
|---|---|---|---|---|---|---|
TNXP
Tonix Pharmaceuticals Holding Corp
|
15.14 | 193.10M | 0 | -121.02M | -114.09M | -11.26 |
|
VRTX
Vertex Pharmaceuticals Inc
|
491.47 | 117.98B | 11.74B | 3.68B | 3.34B | 14.19 |
|
REGN
Regeneron Pharmaceuticals Inc
|
803.17 | 82.85B | 14.34B | 4.50B | 3.77B | 41.56 |
|
ARGX
Argen X Se Adr
|
821.96 | 51.58B | 3.06B | 1.28B | 447.35M | 19.67 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
314.40 | 40.75B | 3.21B | 43.57M | 221.36M | 0.2405 |
|
ONC
Beone Medicines Ltd Adr
|
346.07 | 38.33B | 4.98B | 69.60M | 525.67M | 0.5198 |
토닉스 파마슈티컬스 홀딩 Stock (TNXP) Upgrades & Downgrades
| 날짜 | 액션 | 분석자 | 등급 변경 |
|---|---|---|---|
| 2022-04-18 | 개시 | Noble Capital Markets | Outperform |
| 2019-04-18 | 업그레이드 | ROTH Capital | Neutral → Buy |
| 2017-08-18 | 업그레이드 | ROTH Capital | Neutral → Buy |
| 2016-09-07 | 다운그레이드 | ROTH Capital | Buy → Neutral |
| 2016-02-17 | 재확인 | Oppenheimer | Outperform |
| 2015-11-04 | 개시 | Cantor Fitzgerald | Buy |
| 2015-06-12 | 개시 | Oppenheimer | Outperform |
| 2015-02-17 | 재확인 | ROTH Capital | Buy |
| 2014-09-29 | 재확인 | ROTH Capital | Buy |
모두보기
토닉스 파마슈티컬스 홀딩 주식(TNXP)의 최신 뉴스
Is Tonix Pharmaceuticals Holding Corp. forming a breakout patternTrade Risk Summary & Stock Portfolio Risk Management - mfd.ru
What are Tonix Pharmaceuticals Holding Corp.’s earnings expectationsSwing Trade & Community Trade Idea Sharing Platform - mfd.ru
TNXP News Today | Why did Tonix Pharmaceuticals stock go up today? - MarketBeat
Behavioral Patterns of TNXP and Institutional Flows - Stock Traders Daily
Market Recap: Will Tonix Pharmaceuticals Holding Corp stock benefit from M APortfolio Value Report & Safe Capital Growth Stock Tips - baoquankhu1.vn
Earnings Recap: Can Tonix Pharmaceuticals Holding Corp deliver alphaJuly 2025 Opening Moves & Verified Momentum Stock Ideas - baoquankhu1.vn
Dying for Some Sleep - RealClearHealth
Tonix opens Berkeley Heights HQ, expands NJ biotech footprint - NJBIZ
Aug Opening: How volatile is Haverty Furniture Companies Inc stockPortfolio Risk Report & Verified High Yield Trade Plans - baoquankhu1.vn
Tonix’s fibromyalgia drug shows significant pain reduction in study By Investing.com - Investing.com Australia
Tonix Highlights Significant Phase 3 RESILIENT Results For TONMYA At Non-Opioid Pain Summit - Nasdaq
Tonix Presents Positive Phase 3 RESILIENT Data On TONMYA At 2026 Non-Opioid Pain Therapeutics Summit - Nasdaq
Tonix Pharmaceuticals (TNXP) Reports Positive Phase 3 Trial Resu - GuruFocus
Tonix’s fibromyalgia drug shows significant pain reduction in study - Investing.com
Tonix Pharmaceuticals Presented Phase 3 RESILIENT Data on TONMYA™ (Cyclobenzaprine HCl Sublingual Tablets) at the 2026 Non-Opioid Pain Therapeutics Summit - The Manila Times
Pharma company Tonix opening HQ in Berkeley Heights - ROI-NJ
Fibromyalgia Market: Expanding Revenue Landscape to 2034 – DelveInsight | UCB Pharma, Eli Lilly and Company, Merck, Aptinyx, Astellas Pharma, Tonix Pharma, UCB Biopharma SRL, GSK, UCB Pharma - Barchart.com
(TNXP) Movement Within Algorithmic Entry Frameworks - Stock Traders Daily
A. G. P. Maintains Tonix Pharmaceuticals(TNXP.US) With Buy Rating, Maintains Target Price $65 - 富途牛牛
Trend Review: Is now the right time to enter Tonix Pharmaceuticals Holding CorpEarnings Overview Report & High Return Trade Guides - baoquankhu1.vn
Aug Wrap: Is Tonix Pharmaceuticals Holding Corp forming a breakout patternJuly 2025 Trade Ideas & Reliable Breakout Stock Forecasts - baoquankhu1.vn
Tonix Eyes TNX‑102 SL Expansion, But We Need To See Tonmya Revenue First (NASDAQ:TNXP) - Seeking Alpha
How (TNXP) Movements Inform Risk Allocation Models - Stock Traders Daily
Returns Recap: Will Tonix Pharmaceuticals Holding Corp stock benefit from M A2025 Major Catalysts & Advanced Swing Trade Entry Plans - baoquankhu1.vn
Market Fear: Can Tonix Pharmaceuticals Holding Corp stock outperform in a bear market2025 Top Decliners & Comprehensive Market Scan Reports - baoquankhu1.vn
Tonix Pharmaceuticals (NASDAQ:TNXP) Upgraded by Wall Street Zen to Hold Rating - MarketBeat
Aug PostEarnings: What are Tonix Pharmaceuticals Holding Corps earnings expectationsWeekly Volume Report & Detailed Earnings Play Strategies - baoquankhu1.vn
Analyst Downgrade: Will Tonix Pharmaceuticals Holding Corp face regulatory challengesJuly 2025 Momentum & Technical Confirmation Alerts - baoquankhu1.vn
Fibromyalgia Market Insights Highlight Expanding Outlook Till 2034, DelveInsight Evaluates - openPR.com
Block Trades: What is the fair value of Tonix Pharmaceuticals Holding Corp. stock now2025 Key Highlights & Reliable Intraday Trade Plans - moha.gov.vn
How rising interest rates impact Tonix Pharmaceuticals Holding Corp. stockBreakout Watch & Verified Momentum Watchlists - Улправда
Take Profit: How analysts rate Tonix Pharmaceuticals Holding Corp. stock todayWeekly Market Outlook & Long Hold Capital Preservation Plans - Улправда
Will Tonix Pharmaceuticals Holding Corp. stock see insider buyingWatch List & Stepwise Swing Trade Plans - Улправда
Can Tonix Pharmaceuticals Holding Corp. stock withstand economic slowdownJuly 2025 Volume & Long Hold Capital Preservation Tips - ulpravda.ru
How analysts rate Tonix Pharmaceuticals Holding Corp. stock today2025 Key Highlights & Trade Opportunity Analysis - ulpravda.ru
Trading Systems Reacting to (TNXP) Volatility - Stock Traders Daily
Daily News - FinancialContent
Tonix Pharmaceuticals to Present at Two Investor Conferences in January 2026 - The Manila Times
Tonix highlights pathway for potential single-dose, seasonal protection against Lyme Disease - Proactive financial news
Tonix Pharmaceuticals to meet with FDA in 2026 to advance experimental Lyme disease prevention drug - MSN
Tonix Pharmaceuticals (NASDAQ:TNXP) Cut to "Sell" at Wall Street Zen - MarketBeat
Tonix Pharmaceuticals Shares Climb on Encouraging TNX-801 Vaccine Results - MSN
Aug Gainers: How Tonix Pharmaceuticals Holding Corp stock reacts to inflationary pressuresMarket Activity Recap & Weekly Watchlist for Hot Stocks - moha.gov.vn
Tonix prices 615,025 shares at $16.26 in registered direct offering - Yahoo Finance
Tonix Pharma announces $20 million registered direct offering - MSN
Tonix Pharmaceuticals advances TNX-4800 for Lyme disease prevention By Investing.com - Investing.com Nigeria
Tonix Pharmaceuticals secures $20 million investment from Point72 By Investing.com - Investing.com Nigeria
Tonix Pharma advances TNX-4800 Lyme disease program - MSN
Tonix Pharma Announces $20 Million Registered Direct Offering - TipRanks
Form 424B5 Tonix Pharmaceuticals - StreetInsider
Tonix Pharmaceuticals To Meet With FDA In 2026 To Advance Experimental Lyme Disease Prevention Drug - Asianet Newsable
토닉스 파마슈티컬스 홀딩 (TNXP) 재무 분석
매출
순이익
현금흐름
주당 순 이익
1.12%
0.87%
자본화:
|
볼륨(24시간):